Explaining and predicting preeclampsia

New England Journal of Medicine

Volumn 355, Issue 10, 2006, Pages 1056-1058

  Lindheimer, Marshall D ^a   Umans, Jason G ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; COMORBIDITY; EDITORIAL; FETUS MORTALITY; GENE OVEREXPRESSION; HELLP SYNDROME; HUMAN; HYPERTENSION; INFLAMMATION; MATERNAL MORTALITY; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PREECLAMPSIA; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; PROTEINURIA; VASODILATATION; WORLD HEALTH ORGANIZATION;

ANTIGENS, CD; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33748426800     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe068161     Document Type: Editorial

References (11)

1. Villar J, Say L, Gülmezoglu AM, et al. Eclampsia and preeclampsia: a health problem for 2000 years. In: Critchley H, MacLean A, Poston L, Walker J, eds. Pre-eclampsia. London: RCOG Press, 2003:189-207.
2. Hanson MA, Gluckman PD. Developmental processes and the induction of cardiovascular function: conceptual aspects. J Physiol 2005;565:27-34.
3. Zandi-Nejad K, Luyckx VA, Brenner BM. Adult hypertension and kidney disease: the role of fetal programming. Hypertension 2006;47:502-8.
4. Davison JM, Lindheimer MD, eds. New developments in preeclampsia. Semin Nephrol 2004;24:537-625.
5. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
6. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
7. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9.
8. Conde-Agudelo A, Villar J, Lindheimer MD. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367-91. [Erratum, Obstet Gynecol 2005;106:869.]
9. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
10. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77-85.
11. Zhihe L, Zhang Y, Qiming S, et al. Recombinant vascular endothelial growth factor-121 attenuates hypertension in pregnant rats overproducing soluble fms-like tyrosine kinase-1 gene. Hypertens Preg 2006;25:Suppl 1:51. abstract.